EphB2 promotes progression of cutaneous squamous cell carcinoma

Journal of Investigative Dermatology

Volumn 135, Issue 7, 2015, Pages 1882-1892

  Farshchian, Mehdi ^a,b   Nissinen, Liisa ^a,b   Siljamäki, Elina ^a,c   Riihilä, Pilvi ^a,b   Toriseva, Mervi ^c   Kivisaari, Atte ^a,b   Ala Aho, Risto ^a,b   Kallajoki, Markku ^a   Veräjänkorva, Esko ^a   Honkanen, Hanne Kaisa ^d   Heljasvaara, Ritva ^d   Pihlajaniemi, Taina ^d   Grénman, Reidar ^a   Peltonen, Juha ^c   Peltonen, Sirkku ^a   Kähäri, Veli Matti ^a,b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

^d UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; EPHRIN RECEPTOR B2; INTERSTITIAL COLLAGENASE; MESSENGER RNA; EPHB2 PROTEIN, HUMAN; EPHRIN B2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CELLS; CONTROLLED STUDY; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; KERATINOCYTE; MOUSE; NONHUMAN; PRECANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; SKIN CANCER; SKIN CARCINOMA; SKIN DEFECT; TUMOR XENOGRAFT; VASCULARIZATION; ANIMAL; CELL MOTION; COMPARATIVE STUDY; DISEASE COURSE; DISEASE MODEL; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; NONPARAMETRIC TEST; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZATION; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOWN-REGULATION; EPHRIN-B2; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; MICE; MICE, KNOCKOUT; RANDOM ALLOCATION; RECEPTOR, EPHB2; RNA, MESSENGER; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; STATISTICS, NONPARAMETRIC;

EID: 84931033706     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2015.104     Document Type: Article

References (49)

1. Abel EL, Angel JM, Kiguchi K, et al. (2009) Multi-stage chemical carcinogenesis in mouse skin: fundamentals and applications. Nat Protoc 4:1350-62
2. Airola K, Johansson N, Kariniemi AL, et al. (1997) Human collagenase-3 is expressed in malignant squamous epithelium of the skin. J Invest Dermatol 109:225-31
3. Ala-Aho R, Ahonen M, George SJ, et al. (2004) Targeted inhibition of human collagenase-3 (MMP-13) expression inhibits squamous cell carcinoma growth in vivo. Oncogene 23:5111-23
4. Alam M, Ratner D (2001) Cutaneous squamous-cell carcinoma. N Engl J Med 344:975-83
5. Alazzouzi H, Davalos V, Kokko A, et al. (2005) Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors. Cancer Res 65: 10170-3
6. Batlle E, Bacani J, Begthel H, et al. (2005) EphB receptor activity suppresses colorectal cancer progression. Nature 435:1126-30
7. Beauchamp A, Lively MO, Mintz A, et al. (2012) EphrinA1 is released in three forms from cancer cells by matrix metalloproteases. Mol Cell Biol 32: 3253-64
8. Brideau G, Mäkinen MJ, Elamaa H, et al. (2007) Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer Res 67:11528-35
9. Coulthard MG, Morgan M, Woodruff TM, et al. (2012) Eph/Ephrin signaling in injury and inflammation. Am J Pathol 181:1493-503
10. Czarnecki D, Sutton T, Czarnecki C, et al. (2002) A 10-year prospective study of patients with skin cancer. J Cutan Med Surg 6:427-9
11. Davalos V, Dopeso H, Velho S, et al. (2007) High EPHB2 mutation rate in gastric but not endometrial tumors with microsatellite instability. Oncogene 26: 308-11
12. Durinck S, Ho C, Wang NJ, et al. (2011) Temporal dissection of tumorigenesis in primary cancers. Cancer Discov 1:137-43
13. Egawa G, Osawa M, Uemura A, et al. (2009) Transient expression of ephrin b2 in perinatal skin is required for maintenance of keratinocyte homeostasis. J Invest Dermatol 129:2386-95
14. Farshchian M, Kivisaari A, Ala-Aho R, et al. (2011) Serpin peptidase inhibitor clade A member 1 (SerpinA1) is a novel biomarker for progression of cutaneous squamous cell carcinoma. Am J Pathol 179:1110-9
15. Gordon K, Kochkodan JJ, Blatt H, et al. (2013) Alteration of the EphA2/Ephrin-A signaling axis in psoriatic epidermis. J Invest Dermatol 133:712-22
16. Guo DL, Zhang J, Yuen ST, et al. (2006a) Reduced expression of EphB2 that parallels invasion and metastasis in colorectal tumours. Carcinogenesis 27: 454-64
17. Guo H, Miao H, Gerber L, et al. (2006b) Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin. Cancer Res 66:7050-8
18. Hafner C, Becker B, Landthaler M, et al. (2006) Expression profile of Eph receptors and ephrin ligands in human skin and downregulation of EphA1 in nonmelanoma skin cancer. Mod Pathol 19:1369-77
19. Huusko P, Ponciano-Jackson D, Wolf M, et al. (2004) Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet 36:979-83
20. Johansson N, Airola K, Grenman R, et al. (1997) Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am J Pathol 151:499-508
21. Jubb AM, Zhong F, Bheddah S, et al. (2005) EphB2 is a prognostic factor in colorectal cancer. Clin Cancer Res 11:5181-7
22. Kivisaari A, Kähäri VM (2013) Squamous cell carcinoma of the skin: Emerging need for novel biomarkers. World J Clin Oncol 4:85-90
23. Li X, Choi WW, Yan R, et al. (2014) The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder. PLoS One 9:e105326
24. Lin KT, Sloniowski S, Ethell DW, et al. (2008) Ephrin-B2-induced cleavage of EphB2 receptor is mediated by matrix metalloproteinases to trigger cell repulsion. J Biol Chem 283:28969-79
25. Lin S, Gordon K, Kaplan N, et al. (2010) Ligand targeting of EphA2 enhances keratinocyte adhesion and differentiation via desmoglein 1. Mol Biol Cell 21:3902-14
26. Lin S, Wang B, Getsios S (2012) Eph/ephrin signaling in epidermal differentiation and disease. Semin Cell Dev Biol 23:92-101
27. Lugli A, Spichtin H, Maurer R, et al. (2005) EphB2 expression across 138 human tumor types in a tissue microarray: high levels of expression in gastrointestinal cancers. Clin Cancer Res 11:6450-8
28. Madan V, Lear JT, Szeimies RM (2010) Non-melanoma skin cancer. Lancet 375: 673-85
29. Merlos-Suarez A, Batlle E (2008) Eph-ephrin signalling in adult tissues and cancer. Curr Opin Cell Biol 20:194-200
30. Nievergall E, Lackmann M, Janes PW (2012) Eph-dependent cell-cell adhesion and segregation in development and cancer. Cell Mol Life Sci 69:1813-42
31. Nikolov DB, Xu K, Himanen JP (2013) Eph/ephrin recognition and the role of Eph/ephrin clusters in signaling initiation. Biochim Biophys Acta 1834:2160-5
32. Pasquale EB (2010) Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 10:165-80
33. Poliakov A, Cotrina M, Wilkinson DG (2004) Diverse roles of eph receptors and ephrins in the regulation of cell migration and tissue assembly. Dev Cell 7: 465-80
34. Ratushny V, Gober MD, Hick R, et al. (2012) From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. J Clin Invest 122:464-72
35. Riihilä P, Nissinen L, Farshchian M, et al. (2014a) Complement Factor I promotes progression of cutaneous squamous cell carcinoma. J InvestDermatol 135: 579-88
36. Riihilä PM, Nissinen LM, Ala-Aho R, et al. (2014b) Complement factor H: a biomarker for progression of cutaneous squamous cell carcinoma. J Invest Dermatol 134:498-506
37. Rogers HW, Weinstock MA, Harris AR, et al. (2010) Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 146: 283-7
38. Rowe DE, Carroll RJ, Day CL Jr. (1992) Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 26:976-90
39. South AP, Purdie KJ, Watt SA, et al. (2014) NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis. J Invest Dermatol 134: 2630-8
40. Stokes A, Joutsa J, Ala-Aho R, et al. (2010) Expression profiles and clinical correlations of degradome components in the tumor microenvironment of head and neck squamous cell carcinoma. Clin Cancer Res 16: 2022-35
41. Udayakumar D, Zhang G, Ji Z, et al. (2011) EphA2 is a critical oncogene in melanoma. Oncogene 30:4921-9
42. Walker-Daniels J, Coffman K, Azimi M, et al. (1999) Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 41:275-80
43. Walsh R, Blumenberg M (2012) Eph-2B, acting as an extracellular ligand, induces differentiation markers in epidermal keratinocytes. J Cell Physiol 227:2330-40
44. Wang NJ, Sanborn Z, Arnett KL, et al. (2011) Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci USA 108:17761-6
45. Wang SD, Rath P, Lal B, et al. (2012) EphB2 receptor controls proliferation/migration dichotomy of glioblastoma by interacting with focal adhesion kinase. Oncogene 31:5132-43
46. Wu Q, Suo Z, Risberg B, et al. (2004) Expression of Ephb2 and Ephb4 in breast carcinoma. Pathol Oncol Res 10:26-33
47. Wykosky J, Debinski W (2008) The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res 6: 1795-806
48. Zelinski DP, Zantek ND, Stewart JC, et al. (2001) EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 61: 2301-6
49. Zimmer M, Palmer A, Kohler J, et al. (2003) EphB-ephrinB bi-directional endocytosis terminates adhesion allowing contact mediated repulsion. Nat Cell Biol 5:869-78